Baicalein / RadioS Cancer Research Results

Ba, Baicalein: Click to Expand ⟱
Features:

Baicalein — Baicalein is a polyphenolic flavone aglycone found primarily in Scutellaria baicalensis and related botanicals, and is the active unconjugated counterpart of baicalin after intestinal/microbial deconjugation and re-conjugation cycling. It is formally classified as a small-molecule natural-product flavonoid with pleiotropic signaling, redox, metabolic, and enzyme-modulatory activity. Standard abbreviations include Ba or BE. In cancer literature it is best characterized as a multi-target preclinical anticancer scaffold rather than an established oncology drug, with relatively strong mechanistic support for apoptosis induction, survival-pathway suppression, anti-invasive signaling, and 12-lipoxygenase inhibition, but with major translational constraints from poor aqueous solubility, extensive first-pass glucuronidation/sulfation, transporter-enzyme interactions, and the likelihood that many in-vitro exposure levels exceed typical systemic aglycone exposure.

Primary mechanisms (ranked):

  1. 12-lipoxygenase inhibition with downstream suppression of pro-survival, pro-migratory, and pro-angiogenic lipid signaling.
  2. Intrinsic apoptosis induction via mitochondrial destabilization, cytochrome-c release, caspase-9/3 activation, and BAX:BCL-2 shift.
  3. PI3K/AKT survival-axis repression, often with PTEN restoration and reduced downstream anti-apoptotic signaling.
  4. Redox stress modulation with tumor-context ROS↑ and impaired antioxidant buffering, but normal-cell antioxidant protection in oxidative-injury models.
  5. ER-stress and Ca²⁺ stress coupling that amplifies mitochondrial commitment to cell death.
  6. Suppression of glycolysis / hypoxia adaptation, including HIF-1α, HK2, LDHA, PDK1, PKM2, and GLUT1 in relevant models.
  7. Anti-invasive / anti-metastatic signaling through MMP2/MMP9 and related migration programs.
  8. Anti-angiogenic signaling with VEGF reduction.
  9. Contextual chemo- and radiosensitization in selected models.

Bioavailability / PK relevance: Oral translation is constrained by very low water solubility and extensive intestinal/hepatic phase-II metabolism to glucuronide and sulfate conjugates. Human phase-I data show rapid absorption of tablet formulations with peak plasma levels around 2 hours, steady state after repeated dosing, and major circulating/excreted metabolite burden rather than sustained high parent-aglycone exposure. Microbiota, UGT-dependent reconjugation, and transporter/CYP interactions are clinically relevant variables. Intestinal microbiota are mechanistically relevant because baicalin is converted to baicalein before absorption. Poor translational PK is reinforced by very low aqueous solubility, reported around 16.82 μg/mL, and by formulation studies showing large exposure gains after cocrystal/nanodelivery approaches.

In-vitro vs systemic exposure relevance: Many anticancer cell studies use roughly 10–50 μM and sometimes higher. That generally exceeds typical reported average human plasma exposure for parent baicalein after oral dosing, so direct translation of higher-concentration in-vitro effects should be treated cautiously unless formulation enhancement, local delivery, tissue enrichment, conjugate deconjugation, or combination use is specifically justified.

Clinical evidence status: Strong preclinical evidence across multiple tumor models; limited animal efficacy support; human clinical experience is mainly phase-I safety/PK and non-oncology development contexts. There is no established cancer indication or mainstream regulatory oncology deployment as of March 12, 2026.

Here are some of the key pathways and mechanisms implicated in its anticancer effects:
-Apoptosis and Cell Cycle Regulation
-Reactive Oxygen Species ROS↑ Generation and Oxidative Stress (Context and dose dependent)
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, Ca+2↑, Cyt‑c↑, Caspase-3↑, Caspase-9↑, DNA damage↑,
-Baicalein’s effects on ROS are context-dependent. In some cancer cells, it promotes ROS production to a degree that overwhelms the antioxidant defenses. Elevated ROS levels can damage cellular components and promote apoptosis, essentially tipping the balance toward cell death.
-Conversely, in normal cells, baicalein may exhibit antioxidant properties and reduce ROS↓ under conditions of oxidative stress, highlighting its dual role.
- May Lowers AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓, HO-1↓
- Raises AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑, HO-1↑,
-MAPK, ERK Pathway:
-PI3K/Akt Pathway: Inhibition of the PI3K, Akt pathway by baicalein.
-NF-κB Pathway: Baicalein can inhibit
-Inhibition of Metastasis and Invasion: Baicalein can downregulate MMPs, MMP2, MMP9
-Angiogenesis Suppression: VEGF
-Baicalein is a well-known inhibitor of 12-lipoxygenase
-inhibitor of Glycolysis↓ and HIF-1α↓, PKM2↓, cMyc↓, PDK1↓, GLUT1↓, LDHA↓, HK2↓
- promoting PTEN
-chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, neuroprotective, Cognitive, Renoprotection, Hepatoprotective, cardioProtective,
- Selectivity: Cancer Cells vs Normal Cells
-low bioavailability but liposomal may improve bioavailability

In summary, baicalein affects cancer cells by modulating multiple pathways—promoting apoptosis, causing cell cycle arrest, generating or modulating ROS levels, inhibiting survival and proliferative signaling (such as MAPK, PI3K/Akt, and NF-κB pathways), and reducing angiogenesis and metastasis.

Many animal studies, doses have been reported in the range of approximately 10 to 200 mg/kg body weight.
For example, some studies exploring anticancer or anti-inflammatory effects in rodent models have used doses around 50–100 mg/kg.
However, these doses do not directly translate to human dosages.
Some human studies or formulations (where they are used as nutraceuticals or supplements) may suggest dosing in the range of a few hundred milligrams per day of the extract, but it is often not standardized to a specific amount of baicalein or baicalin.
-mix with oil?

-ic50 cancer cells 10-30uM, normal cells 50-100uM
-Animal studies, 10 to 100 mg/kg.
-Reported to induce apoptosis, cause cell cycle arrest, inhibit angiogenesis, and modulate various signaling pathways (e.g., STAT3, NF-κB, MAPK).

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 12-Lipoxygenase axis ↓ 12-LOX, ↓ 12-HETE-linked survival / migration signaling ↔ or modest effect P, R Direct target-level antitumor leverage One of the more mechanistically specific baicalein actions. Supports anti-proliferative, anti-migratory, and anti-angiogenic behavior in susceptible tumors.
2 Mitochondria / MPTP ↓ ΔΨm, ↑ mitochondrial dysfunction, ↑ Cyt-c release ↔ or protected in oxidative-injury models R, G Intrinsic apoptosis commitment Mitochondrial collapse is a major convergence point downstream of redox, ER-stress, and survival-pathway suppression.
3 Caspase apoptosis program ↑ BAX, ↓ Bcl-2, ↑ Casp9, ↑ Casp3, ↑ apoptosis ↔ minimal activation G Cell-death execution Widely reported across tumor models; often follows mitochondrial injury rather than representing the earliest event.
4 PI3K / AKT / PTEN axis ↓ PI3K, ↓ p-AKT, ↑ PTEN ↔ or context-dependent R, G Survival suppression A central non-redox pathway that helps explain apoptosis sensitization, cell-cycle arrest, and metabolic downshift.
5 ROS balance ↑ ROS (dose-dependent) or ROS⇅ depending on model ↓ ROS under oxidative challenge P, R, G Tumor-selective redox stress Dual behavior is important: pro-oxidant pressure is common in malignant cells, whereas antioxidant cytoprotection is well documented in stressed non-malignant cells.
6 NRF2 / HO-1 / GSH antioxidant buffering ↓ NRF2, ↓ HO-1, ↓ GSH (context-dependent) ↑ NRF2, ↑ HO-1, ↑ GSH, ↑ SOD / catalase R, G Selectivity gate This divergent redox-buffer response likely contributes to cancer-versus-normal selectivity, but it is model-dependent and should not be overstated as universal.
7 ER stress and Ca²⁺ stress coupling ↑ ER stress, ↑ CHOP, ↑ UPR, ↑ Ca²⁺ dysregulation ↔ buffered homeostasis R, G Stress amplification Likely helps transmit redox/survival perturbation into irreversible mitochondrial death signaling.
8 Glycolysis / HIF-1α adaptation ↓ HIF-1α, ↓ HK2, ↓ LDHA, ↓ PDK1, ↓ PKM2, ↓ GLUT1, ↓ glycolysis ↔ G Metabolic constraint Most convincing in hypoxia-adaptation and gastric / radioresistance models. Usually reflects later transcriptional or adaptation-level effects.
9 NF-κB and MAPK / ERK signaling ↓ NF-κB, MAPK / ERK modulation (often ↓ ERK tone) ↔ or context-dependent P, R, G Signal reprogramming Supports lower inflammatory-survival tone, apoptosis sensitization, and reduced proliferation, but exact direction within MAPK branches can vary by tumor model.
10 Invasion / metastasis axis ↓ MMP2, ↓ MMP9, ↓ migration / invasion ↔ G Anti-invasive phenotype Phenotypically important and relatively consistent, though usually secondary to broader signaling reprogramming.
11 Angiogenesis axis ↓ VEGF, ↓ microvessel support ↔ G Anti-angiogenic support Supported by xenograft and lung-cancer data; best viewed as an adjunct downstream effect rather than sole primary mechanism.
12 Radiosensitization / chemosensitization ↑ treatment sensitivity (context-dependent) Potential normal-tissue protection in oxidative-injury contexts G Combination-use leverage Mechanistically plausible via HIF-1α/glycolysis suppression, NF-κB restraint, and apoptosis priming, but still preclinical and heterogeneous.
13 Clinical Translation Constraint Low parent exposure, variable microbiota handling, rapid conjugation, likely concentration gap May favor safety but complicates efficacy extrapolation G Delivery limitation Poor solubility, strong first-pass metabolism, conjugate predominance, possible CYP/transporter interactions, and lack of oncology-grade clinical validation are the main barriers.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical–chemical effects; direct enzymatic or rapid signaling shifts)
  • R: 30 min–3 hr (redox signaling and acute stress-response signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)
Scientific Papers found: Click to Expand⟱
2622- Ba,  Cisplatin,  Rad,    Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
RadioS↑, BRF induced radiosensitization in all cells under 6 MV photon beam (SER of 1.06 to 1.35), and MDA-MB-231 cells only under 6 MeV electron beam (SER = 1.20)

5507- Ba,    Baicalein Enhances Radiosensitivity in Colorectal Cancer via JAK2/STAT3 Pathway Inhibition
- vitro+vivo, Var, NA
RadioS↑, Our results demonstrated that BE significantly increased radiosensitivity in vitro and in vivo and enhanced apoptosis in tumor tissues
p‑STAT3↓, BE significantly downregulated the expression of p-STAT3, JAK2, and PD-L1, and significantly upregulated SOCS3 expression.
JAK2↓,
PD-L1↓,
SOCS-3↑,

5251- Ba,    The Fascinating Effects of Baicalein on Cancer: A Review
- Review, Var, NA
AntiTum↑, The anti-tumor functions of baicalein are mainly due to its capacities to inhibit complexes of cyclins to regulate the cell cycle, to scavenge oxidative radicals, to attenuate mitogen activated protein kinase (MAPK), protein kinase B (Akt) or mammali
TumCCA↓,
ROS↓,
MAPK↓,
Akt↓,
mTOR↓,
Casp3↑, , to induce apoptosis by activating caspase-9/-3 and to inhibit tumorinvasion and metastasis by reducing the expression of matrix metalloproteinase-2/-9 (MMP-2/-9).
Casp9↑,
TumCI↓,
TumMeta↓,
MMP2↓,
MMP9↓,
Securin↓, Baicalein also induced cell death by reducing the expression of securin, while also inhibiting cancer cell death by affecting the expression of p-AKT and γ-H2AX [26].
γH2AX↝,
N-cadherin↓, Baicalein also decreased the expression of metastasis-associated molecules, including N-cadherin, vimentin, ZEB1, and ZEB2.
Vim↓,
Zeb1↓,
ZEB2↓,
TumCMig↓, researchers demonstrated that baiclalein inhibited cellular adhesion, migration, invasion, and growth of HCC cells both in vitro and in vivo.
TumCG↑,
12LOX↓, Baicalein is an inhibitor of 12-LOX and induced apoptosis, morphological changes, and carbonic anhydrase expression in PaCa cells.
DR5↑, Baicalein lessened this resistance to TRAIL by upregulating DR5 expression and promoting the expression of ROS, thus causing TRAIL sensitization in PC3 cells [85]
ROS↑,
RadioS↑, baicalein increased the sensitivity of prostate cancer cells to radiation without affecting this sensitivity in normal cells
ChemoSen↑, Combination therapy of baicalein with paclitaxel, which were assembled by nanoparticles, was demonstrated to have synergistic anticancer effects in A549 lung cancer cells and in mice bearing A549/PTX drug-resistant lung cancer xenografts [97].
BioAv↓, It is worth noting that the bioavailability of baicalein in vivo remains low.

5249- Ba,  BA,    Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges
- Review, Var, NA
Apoptosis↑, Mechanistically, they modulate interconnected signaling cascades governing apoptosis, inflammation, and cell cycle control, and they enhance tumor sensitivity to chemotherapy and radiotherapy.
Inflam↓,
TumCCA↑,
ChemoSen↑,
RadioS↑,
TumCG↓, In-vivo models consistently demonstrate tumor growth inhibition, while clinical data suggest a favorable safety profile, even at relatively high oral doses.
toxicity↓,
BioAv↓, their clinical translation remains hampered by limited solubility, poor oral bioavailability, and rapid metabolism,
Half-Life↓, However, baicalein showed a partial bioavailability, poor solubility and pharmacokinetics, and a short half-life [6]

2481- Ba,  Rad,    Radiotherapy Increases 12-LOX and CCL5 Levels in Esophageal Cancer Cells and Promotes Cancer Metastasis via THP-1-Derived Macrophages
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, KYSE150
12LOX↓, increased by 12-LOX upregulation but was suppressed by the well-established 12-LOX inhibitor, baicalein
RadioS↑, In prostate cancer cells, 12-LOX inhibition has been shown to increase radiation sensitivity,
Dose↝, Additionally, 12-LOX expression was significantly inhibited at 40 µmol/L
RANTES↓, post-radiotherapy protein levels of CCL5 increased in Eca109 and Kyse150 cells but were inhibited by baicalein
MCP1↓, Baicalein, a recognized inhibitor of 12-LOX, successfully inhibited CCL2 and CCL5 expression, which was verified by RT-qPCR.

2391- Ba,    Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors
- Review, GC, NA
Hif1a↓, pretreatment of baicalein increased the sensitivity of tumor cells to 6Gy ray by down-regulating HIF-1A and PKM2, the key regulators of glycolysis.
PKM2↓,
RadioS↑,
Glycolysis↓,
PAK↓, baicalein dose-dependently inhibited the growth of EC in mice with a decrease in PAK4 protein

2297- Ba,    Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine
- Review, Var, NA
Glycolysis↓, baicalein to re-sensitize tamoxifen-resistant breast cancer cells in vitro and in vivo through the attenuation of aerobic glycolysis and reversion of mitochondrial dysfunction via reduced HIF-1α expression and transcriptional activity
Hif1a↓, inhibition of HIF-1α and PKM2 by baicalein resulted in the glycolysis suppression
PKM2↓, baicalein enhanced radio-sensitivity and inhibited the progression of esophageal squamous cell carcinoma by affecting HIF-1α and PKM2.
RadioS↑,


Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,   ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 2,   Glycolysis↓, 2,   PKM2↓, 2,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Casp3↑, 1,   Casp9↑, 1,   DR5↑, 1,   MAPK↓, 1,  

Kinase & Signal Transduction ⓘ

PAK↓, 1,  

DNA Damage & Repair ⓘ

γH2AX↝, 1,  

Cell Cycle & Senescence ⓘ

Securin↓, 1,   TumCCA↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,   p‑STAT3↓, 1,   TumCG↓, 1,   TumCG↑, 1,  

Migration ⓘ

MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumMeta↓, 1,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   JAK2↓, 1,   MCP1↓, 1,   PD-L1↓, 1,   RANTES↓, 1,   SOCS-3↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   ChemoSen↑, 2,   Dose↝, 1,   Half-Life↓, 1,   RadioS↑, 7,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   toxicity↓, 1,  
Total Targets: 44

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RadioS, RadioSensitizer
7 Baicalein
2 Radiotherapy/Radiation
1 Cisplatin
1 Baicalin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:38  Target#:1107  State#:%  Dir#:%
  wNotes=onS  sortOrder:rid,rpid

 

Home Page